Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
GNVC's Cash-to-Debt is ranked higher than
99% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. GNVC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GNVC' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.64  Med: 18.17 Max: No Debt
Current: No Debt
Equity-to-Asset 0.61
GNVC's Equity-to-Asset is ranked lower than
54% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. GNVC: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
GNVC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.73 Max: 0.88
Current: 0.61
0.42
0.88
Piotroski F-Score: 1
Altman Z-Score: -51.23
Beneish M-Score: -4.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1411.94
GNVC's Operating Margin % is ranked lower than
80% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. GNVC: -1411.94 )
Ranked among companies with meaningful Operating Margin % only.
GNVC' s Operating Margin % Range Over the Past 10 Years
Min: -1411.94  Med: -151.31 Max: -42
Current: -1411.94
-1411.94
-42
Net Margin % -1132.49
GNVC's Net Margin % is ranked lower than
78% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. GNVC: -1132.49 )
Ranked among companies with meaningful Net Margin % only.
GNVC' s Net Margin % Range Over the Past 10 Years
Min: -1132.49  Med: -141.73 Max: -41.63
Current: -1132.49
-1132.49
-41.63
ROE % -91.73
GNVC's ROE % is ranked lower than
76% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. GNVC: -91.73 )
Ranked among companies with meaningful ROE % only.
GNVC' s ROE % Range Over the Past 10 Years
Min: -177.18  Med: -73.15 Max: -25.24
Current: -91.73
-177.18
-25.24
ROA % -64.86
GNVC's ROA % is ranked lower than
73% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. GNVC: -64.86 )
Ranked among companies with meaningful ROA % only.
GNVC' s ROA % Range Over the Past 10 Years
Min: -101.98  Med: -56.85 Max: -21.39
Current: -64.86
-101.98
-21.39
ROC (Joel Greenblatt) % -2337.84
GNVC's ROC (Joel Greenblatt) % is ranked lower than
71% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. GNVC: -2337.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNVC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2358.56  Med: -1585.27 Max: -642.28
Current: -2337.84
-2358.56
-642.28
3-Year Revenue Growth Rate -55.80
GNVC's 3-Year Revenue Growth Rate is ranked lower than
86% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. GNVC: -55.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GNVC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -66.8  Med: -21.6 Max: 6
Current: -55.8
-66.8
6
3-Year EBITDA Growth Rate -30.50
GNVC's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. GNVC: -30.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GNVC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -43.5  Med: -28.9 Max: 12.1
Current: -30.5
-43.5
12.1
3-Year EPS without NRI Growth Rate -28.80
GNVC's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. GNVC: -28.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GNVC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: -27.1 Max: 8.9
Current: -28.8
-42.8
8.9
GuruFocus has detected 4 Warning Signs with Genvec Inc $GNVC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GNVC's 10-Y Financials

Financials (Next Earnings Date: 2017-06-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GNVC Guru Trades in Q1 2016

Jim Simons 120,900 sh (+84.02%)
» More
Q2 2016

GNVC Guru Trades in Q2 2016

Jim Simons 156,500 sh (+29.45%)
» More
Q3 2016

GNVC Guru Trades in Q3 2016

Jim Simons 184,500 sh (+17.89%)
» More
Q4 2016

GNVC Guru Trades in Q4 2016

Jim Simons 27,760 sh (+50.46%)
» More
» Details

Insider Trades

Latest Guru Trades with GNVC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:ATTBF, OTCPK:PPGNY, NAS:ORPN, NAS:SNGX, NAS:DPRX, OTCPK:BCTXF, NAS:OCRX, NAS:JAGX, NAS:APTO, NAS:OGXI, NAS:KTOV, AMEX:HEB, OTCPK:OPNT, NAS:CYCC, NAS:MBVX, OTCPK:BLUSF, OTCPK:ENZN, OTCPK:MATN, OTCBB:DDRT, OTCPK:IPATF » details
Traded in other countries:GVC2.Germany,
Genvec Inc is a biopharmaceutical company. The Company is engaged in leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines.

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV. The Company is developing vaccines against RSV, the single main viral cause of lower respiratory infections in infants and young children. It is developing vaccines for the prevention and treatment of HSV including HSV type 2 the virus responsible for cases of genital herpes. With its collaborators, the Company is generating vaccine candidates for the prevention of dengue fever. Dengue fever is a viral disease spread by mosquitoes that historically affected 50 million to 100 million people each year. With its collaborators the Company is generating vaccine candidates for the prevention of malaria. With its collaborators, the Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. FMD is a contagious viral disease affecting cows and other animals with cloven hooves. The Company currently has two suppliers for its clinical manufacturing components, one for human health and one for animal health candidates. Currently it procures raw materials, including specialized components known as resins, for its product purification and testing methods from a limited number of suppliers. The Company faces intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The research, development, testing, manufacture, quality, safety, effectiveness, labeling, packaging, storage, approval, distribution, marketing, advertising, and promotion of any biologic products developed by the Company or its collaborators are subject to regulation by federal, state, local, and foreign governmental authorities.

Ratios

vs
industry
vs
history
PB Ratio 2.97
GNVC's PB Ratio is ranked higher than
56% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. GNVC: 2.97 )
Ranked among companies with meaningful PB Ratio only.
GNVC' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 3.17 Max: 41.5
Current: 2.97
0.42
41.5
PS Ratio 22.86
GNVC's PS Ratio is ranked lower than
62% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. GNVC: 22.86 )
Ranked among companies with meaningful PS Ratio only.
GNVC' s PS Ratio Range Over the Past 10 Years
Min: 0.62  Med: 5.5 Max: 42.97
Current: 22.86
0.62
42.97
Current Ratio 4.04
GNVC's Current Ratio is ranked higher than
50% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. GNVC: 4.04 )
Ranked among companies with meaningful Current Ratio only.
GNVC' s Current Ratio Range Over the Past 10 Years
Min: 2.21  Med: 4.28 Max: 8.13
Current: 4.04
2.21
8.13
Quick Ratio 4.04
GNVC's Quick Ratio is ranked higher than
52% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GNVC: 4.04 )
Ranked among companies with meaningful Quick Ratio only.
GNVC' s Quick Ratio Range Over the Past 10 Years
Min: 2.21  Med: 4.28 Max: 8.13
Current: 4.04
2.21
8.13
Days Sales Outstanding 15.71
GNVC's Days Sales Outstanding is ranked higher than
83% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. GNVC: 15.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNVC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.71  Med: 41.81 Max: 71.17
Current: 15.71
15.71
71.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.30
GNVC's 3-Year Average Share Buyback Ratio is ranked lower than
68% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. GNVC: -18.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNVC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -139.6  Med: -13.2 Max: -2
Current: -18.3
-139.6
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.34
GNVC's Price-to-Net-Cash is ranked higher than
70% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. GNVC: 3.34 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GNVC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.33  Med: 5.31 Max: 31.86
Current: 3.34
1.33
31.86
Price-to-Net-Current-Asset-Value 3.12
GNVC's Price-to-Net-Current-Asset-Value is ranked higher than
70% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. GNVC: 3.12 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GNVC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.18  Med: 4.39 Max: 18.38
Current: 3.12
1.18
18.38
Price-to-Tangible-Book 2.96
GNVC's Price-to-Tangible-Book is ranked higher than
63% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. GNVC: 2.96 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GNVC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 3.36 Max: 16.66
Current: 2.96
1.14
16.66
Price-to-Median-PS-Value 4.16
GNVC's Price-to-Median-PS-Value is ranked lower than
91% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. GNVC: 4.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GNVC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.4 Max: 6.28
Current: 4.16
0.24
6.28
Earnings Yield (Greenblatt) % -82.14
GNVC's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. GNVC: -82.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNVC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -85.66  Med: 431 Max: 17011.4
Current: -82.14
-85.66
17011.4

More Statistics

Revenue (TTM) (Mil) $0.51
EPS (TTM) $ -2.88
Beta2.23
Short Percentage of Float12.81%
52-Week Range $2.70 - 14.00
Shares Outstanding (Mil)2.27

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 0 1 2
EPS ($) -2.81 -2.70 -3.00
EPS without NRI ($) -2.81 -2.70 -3.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GNVC

Headlines

Articles On GuruFocus.com
GenVec Inc. Reports Operating Results (10-K) Mar 11 2011 
GenVec Inc. Reports Operating Results (10-Q) May 07 2010 
GenVec Inc. Reports Operating Results (10-Q) Nov 06 2009 
GenVec Inc. Reports Operating Results (10-Q) Aug 07 2009 
GenVec Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
GenVec, Inc. :GNVC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
GenVec, Inc. :GNVC-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
GENVEC INC Financials Mar 10 2017
GENVEC INC Files SEC form 10-K, Annual Report Mar 06 2017
Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results Mar 01 2017
Lifshitz & Miller LLP Announces Investigation of Aetna Inc., GenVec, Inc., Ixia, McKesson... Feb 17 2017
WeissLaw LLP: GenVec, Inc. Acquisition May Not Be in the Best Interests of GNVC Shareholders Feb 08 2017
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of GenVec, Inc. And... Feb 06 2017
GENVEC INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC... Feb 02 2017
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of GenVec, Inc.... Feb 02 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... Jan 26 2017
Intrexon To Buy GenVec In Stock Deal For $7/Shr Jan 25 2017
GenVec downgraded by Rodman & Renshaw Jan 25 2017
GENVEC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to... Jan 24 2017
Intrexon to acquire fellow Md. biotech Jan 24 2017
Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform Jan 24 2017
GenVec to Present at Phacilitate Cell & Gene Therapy World 2017 Jan 11 2017
EnteroMedics and GenVec Post Substantial Gains as the NASDAQ is Pushed to Record High Jan 10 2017
GenVec Signs Option Agreement for Gene Editing and Cell Targeting Technology from Washington... Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)